Clinical trials: Predicted Tauopathies, Including
Predicted Tauopathies, Including, Progressive Supranuclear Palsy
Davunetide (AL-108) in Predicted Tauopathies - Pilot Study
The primary objective of the study is to obtain preliminary safety and tolerability data with davunetide (NAP, AL-108) in patients with a tauopathy (frontotemporal lobar degeneration [FTLD] with predicted tau pathology…
- Conditions
- Predicted Tauopathies, Including, Progressive Supranuclear Palsy, Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17, Corticobasal Degeneration Syndrome
- Trial name
- NCT01056965
- Testing
- davunetide (AL-108, NAP)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of California, San Francisco